{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:21:14Z","timestamp":1777101674145,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ajem.2019.01.008","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T12:46:03Z","timestamp":1547037963000},"page":"1907-1911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage"],"prefix":"10.1016","volume":"37","author":[{"given":"Daniel","family":"Dybdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Walliser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Chance Spalding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Pershing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Kincaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2019.01.008_bb0005","series-title":"Praxbind\u00ae (idarucizumab) injection prescribing information","year":"2015"},{"key":"10.1016\/j.ajem.2019.01.008_bb0010","series-title":"Kcentra\u00ae [prothrombin complex concentrate (human)] prescribing information","year":"2014"},{"key":"10.1016\/j.ajem.2019.01.008_bb0015","series-title":"ANDEXXA\u00ae [coagulation factor Xa (recombinant), inactivated-zhzo] prescribing information","year":"2018"},{"key":"10.1016\/j.ajem.2019.01.008_bb0020","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ajem.2019.01.008_bb0025","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.09.1085","article-title":"2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"70","author":"Tomaselli","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajem.2019.01.008_bb0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/STROKEAHA.112.675231","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban","volume":"44","author":"Zhou","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ajem.2019.01.008_bb0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1160\/TH12-12-0907","article-title":"Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates","volume":"110","author":"Perzborn","year":"2013","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ajem.2019.01.008_bb0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.thromres.2015.01.007","article-title":"Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding","volume":"135","author":"Herzog","year":"2015","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.ajem.2019.01.008_bb0045","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/jth.13165","article-title":"Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage","volume":"13","author":"Herzog","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ajem.2019.01.008_bb0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/ALN.0000000000000520","article-title":"Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage","volume":"122","author":"Herzog","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ajem.2019.01.008_bb0055","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jth.12599","article-title":"Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers","volume":"12","author":"Levi","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"21","key":"10.1016\/j.ajem.2019.01.008_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V124.21.345.345","article-title":"Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects","volume":"124","author":"Perlstein","year":"2014","journal-title":"Blood"},{"issue":"Supp1","key":"10.1016\/j.ajem.2019.01.008_bb0065","first-page":"S42","article-title":"4-Factor prothrombin concentrate reverses apixaban inhibition of thrombin generation in healthy volunteers [abstract]","volume":"99","author":"Kraft","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ajem.2019.01.008_bb0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","article-title":"Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate","volume":"131","author":"Zahir","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2019.01.008_bb0075","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.wneu.2015.11.086","article-title":"New target-specific oral anticoagulants and intracranial bleeding: management and outcome in a single-center case series","volume":"88","author":"Senger","year":"2016","journal-title":"World Neurosurg"},{"key":"10.1016\/j.ajem.2019.01.008_bb0080","first-page":"1","article-title":"Clinical effectiveness and safety outcomes associated with prothrombin complex concentrates","author":"Hedges","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.ajem.2019.01.008_bb0085","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.wneu.2015.08.042","article-title":"Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors","volume":"84","author":"Grandhi","year":"2015","journal-title":"World Neurosurg"},{"key":"10.1016\/j.ajem.2019.01.008_bb0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2522\/ptj.20130199","article-title":"Validity of the AM-PAC \u201c6-clicks\u201d inpatient daily activity and basic mobility short forms","volume":"94","author":"Jette","year":"2014","journal-title":"Phys Ther"},{"key":"10.1016\/j.ajem.2019.01.008_bb0095","article-title":"Safety and effectiveness of Factor Eight Inhibitor Bypassing Activity for direct oral anticoagulant-related hemorrhage reversal","author":"Engelbart","year":"2018","journal-title":"Am J Emerg Med"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675719300087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675719300087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:46:09Z","timestamp":1760024769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675719300087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0735675719300087"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2019.01.008","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2019.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}